Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000
Debt
Debt-to-Equity Ratio2.14
Current Ratio3.88
Quick Ratio3.60
Price-To-Earnings
Trailing P/E Ratio14.72
Forward P/E Ratio13.54
P/E Growth2.31
Sales & Book Value
Annual Sales$22.85 billion
Price / Sales5.36
Cash Flow$15.3651 per share
Price / Cash12.05
Book Value$34.77 per share
Price / Book5.32
Profitability
EPS (Most Recent Fiscal Year)$12.58
Net Income$1.98 billion
Net Margins9.67%
Return on Equity35.80%
Return on Assets12.06%
Miscellaneous
Employees20,800
Outstanding Shares661,710,000
Amgen (NASDAQ:AMGN) Frequently Asked Questions
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Wednesday, March 7th. Shareholders of record on Thursday, May 17th will be given a dividend of $1.32 per share on Friday, June 8th. This represents a $5.28 annualized dividend and a yield of 2.85%. The ex-dividend date of this dividend is Wednesday, May 16th. View Amgen's Dividend History.
How will Amgen's stock buyback program work?
Amgen announced that its board has initiated a share repurchase program on Friday, February 2nd 2018, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its shares are undervalued.
How were Amgen's earnings last quarter?
Amgen, Inc. (NASDAQ:AMGN) announced its earnings results on Tuesday, April, 24th. The medical research company reported $3.47 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $3.24 by $0.23. The medical research company earned $5.55 billion during the quarter, compared to analysts' expectations of $5.44 billion. Amgen had a net margin of 9.67% and a return on equity of 35.80%. The firm's revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.15 EPS. View Amgen's Earnings History.
When is Amgen's next earnings date?
What guidance has Amgen issued on next quarter's earnings?
Amgen issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $12.80-13.70 for the period, compared to the Thomson Reuters consensus estimate of $13.47. The company issued revenue guidance of $21.9-22.8 billion, compared to the consensus revenue estimate of $22.71 billion.
What price target have analysts set for AMGN?
21 equities research analysts have issued 1 year target prices for Amgen's shares. Their forecasts range from $174.00 to $220.00. On average, they expect Amgen's stock price to reach $195.5888 in the next year. View Analyst Ratings for Amgen.
What are Wall Street analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. Cann analysts commented, "The timing of this EC approval of Prolia in GIOP is in line with our expectations, following FDA approval in this setting in May 2018. in GIOP in the EU supports our expectations for Prolia sales through 2022. With this approval, patients who receive treatment with glucocorticoids, who need options to improve their bone mineral density, provide a new addressable market for Prolia. Prolia is in its eighth year of launch, and has achieved an estimated market penetration of greater than 60%. We anticipate Prolia sales will increase to $2.75 billion in 2022 from $1.97 billion in 2017 and will account for 8.4% of sales." (6/8/2018)
- 2. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Kyprolis – are performing well. Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support in 2018. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions. However, estimates have gone up ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/17/2018)
- 3. JPMorgan Chase & Co. analysts commented, "AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth." (2/4/2018)
- 4. Mizuho analysts commented, "We expect Q4 ’17 trends for both unit demand and net selling price to continue into 2018 – Expect Q1 ’18 sales to be ~ 20% of full year 2018 sales Neulasta US = 969 / 950 / 949 Neulasta Ex-US = 145 / 151 / 152 Neulasta WW = 1114/ 1103 / 1100 Neupogen US = 82 / 87 / 87 PLEASE REFER TO PAGE 5 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (2/1/2018)
- 5. Argus analysts commented, "We would consider a more constructive stance on AMGN on signs of stronger contributions from the company's new drug pipeline or from its biosimilars portfolio," the firm said."We note, however, that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal hurdles." (11/1/2017)
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), argenx (ARGX) and Halozyme Therapeutics (HALO).
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 55)
- Mr. David W. Meline, Exec. VP, CFO and Principal Financial & Accounting Officer (Age 61)
- Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 57)
- Dr. Sean E. Harper, Exec. VP of R&D (Age 55)
- Mr. Anthony C. Hooper, Exec. VP of Global Commercial Operations (Age 63)
Has Amgen been receiving favorable news coverage?
Media headlines about AMGN stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amgen earned a coverage optimism score of 0.07 on Accern's scale. They also assigned news coverage about the medical research company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Amgen's major shareholders?
Amgen's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.08%), Northern Trust Corp (1.40%), Wells Fargo & Company MN (0.97%), Franklin Resources Inc. (0.61%), LSV Asset Management (0.61%) and Legal & General Group Plc (0.52%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Institutional Ownership Trends for Amgen.
Which major investors are selling Amgen stock?
AMGN stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., BlackRock Inc., Wells Fargo & Company MN, Northern Trust Corp, Swiss National Bank, The Manufacturers Life Insurance Company, State of Tennessee Treasury Department and Great Lakes Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Carbonnel Francois De and Sean E Harper. View Insider Buying and Selling for Amgen.
Which major investors are buying Amgen stock?
AMGN stock was acquired by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, Old Mutual Global Investors UK Ltd., Summit Trail Advisors LLC, SG Americas Securities LLC, Mackay Shields LLC, LSV Asset Management, Element Capital Management LLC and Coho Partners Ltd.. View Insider Buying and Selling for Amgen.
How do I buy shares of Amgen?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of AMGN stock can currently be purchased for approximately $185.15.
How big of a company is Amgen?
Amgen has a market capitalization of $123.07 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe.
How can I contact Amgen?
Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]
MarketBeat Community Rating for Amgen (AMGN)
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
